Vivesto (formerly known as Oasmia Pharmaceutical) develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology. It focuses on manufacturing formulations and drug-delivery systems based on cytostatics. The Company's approved products include Paclical/Apealea, treating cancers, such as lung, breast, and ovarian cancer; and Paccal Vet, a formulation for the treatment of squamous cell carcinoma and mammary carcinoma in dogs. It develops a number of candidates to treat cancer comprising leukemia, prostate, lung, breast cancer, and lymphoma. The Company also develops a formulation to treat lymphoma in dogs.